Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
solid tumor
Biotech
Gilead gives up on $4.9B antibody magrolimab
Gilead dealt a final blow to its anti-CD47 monoclonal antibody magrolimab Thursday by removing the remaining solid tumor trials from its pipeline.
Nick Paul Taylor
Apr 26, 2024 10:04am
Roche's R&D rethink hits 20% of molecules as cancer drugs axed
Apr 24, 2024 4:27am
Poseida examines CAR-T conditioning to crack into solid tumors
Apr 10, 2024 10:32am
Synthekine hopes new IL-2 will be the high-alpha in a beta class
Apr 10, 2024 9:50am
BMS-backed TORL grabs $158M to march army of ADCs through clinic
Apr 10, 2024 9:35am
Ipsen joins ADC race via $900M biobuck deal with Sutro
Apr 2, 2024 7:26am